Projected attendance at AS research conference

About 100 patients, clinicians, and others are already registered as attendees at the conference on

Click on the link above for more information and to register. There is still plenty of time to join us.

The conference will take place from 12:00 pm to 4:00 pm Eastern time on Monday, December 13 AND on 12:00 pm to 4:00 pm on Thursday, December 16.

Continue reading

Registration for major active surveillance (AS) research conference now open

Registration is now OPEN for the upcoming conference on future research into the use of active surveillance for men with favorable-risk forms of localized prostate cancer:

Click on the link above for more information and to register. … READ MORE …

NCCN guidance on the initial management of low-risk, localized prostate cancer

As many readers will already be aware, the National Comprehensive Cancer Network (NCCN) has recently removed the word “preferred” from its statement regarding the use of active surveillance (AS) as an appropriate form of management of men with low-risk forms of localized prostate cancer. A broad swath of specialists in the initial management of low-risk disease, as well as many in the patient advocacy community, have been highly critical of this change to the NCCN guidelines. … READ MORE …

Chances to hear from the new President and CEO of the Prostate Cancer Foundation

At the end of September, the Prostate Cancer Foundation appointed Charles {“Chuck”) Ryan, MD — formerly of the University of California, San Francisco, and the University of Minnesota — as the new President and CEO of the Foundation. And there will be two opportunities for patients to hear directly from Dr. Ryan in the near future. … READ MORE …

More than 25 organizations join new Prostate Cancer Impact Alliance

Prostate Cancer International (PCaI) is proud to be an inaugural member of the new Prostate Cancer Impact Alliance (PCIA). PCIA’s shared vision is to advance education, research and equitable access to high quality care to better patient outcomes for men with prostate cancer. … READ MORE …

Educational opportunities on September 29 upcoming

Two educational programs are scheduled on Wednesday, September 29. The two programs will be be very different: one for very early stage patients; the other for patients with progressive prostate cancer at risk for (or already diagnosed with) de novo metastatic, hormone-sensitive prostate cancer (mHSPC) … READ MORE …

Brief, intense radiation and hormone therapy for very high-risk prostate cancer

As we’ve seen, brachy boost therapy seems to have the best oncological results for men with very high-risk prostate cancer. … READ MORE …

Major results of Phase III VISION trial announced

Earlier today, Novartis issued a media release giving the major results of the Phase III VISION trial, which compared the effectiveness of 177Lu-PSMA-617+ best standard of care (SOC), as selected by individual investigators, to SOC alone in the treatment of men with PSMA-positive men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

New guidelines for salvage radiation dimensions

It has always been troubling that only about half of all salvage radiation treatments after failure of radical prostatectomy are successful. Usually, only the prostate bed is treated. But sometimes recurrent patients (or those with persistently elevated PSA) receive salvage radiation to the pelvic lymph nodes as well, or subsequently. … READ MORE …

First of six FREE webinars on making well-informed prostate cancer decisions

On Wednesday, May 26, the Cancer Support Community together with Prostate Cancer International will be holding the first of a series of six FREE educational webinars for patients and family members. … READ MORE …

A revolutionary advance in patient-centric prostate cancer advocacy/support

For those who have not already heard about it, two of the very largest patient-centric prostate cancer advocacy organizations have agreed to merge into one.

… READ MORE …

Xofigo 2.0

Xofigo (radium Ra 223 dichloride) is a systemic radiopharmaceutical. Radium is chemically similar to calcium and is taken up by bones in places where bone is actively growing, as in prostate cancer bone metastases. … READ MORE …

Genetics, epigenetics, and the evolution of prostate cancer

If you are one of our readers who is really “into” the underlying causes of and development of prostate cancer, then you probably want to see if you can read a newly published article in this week’s New England Journal of Medicine. … READ MORE …

Improvements in surgical technique: past and more recent

Nearly 3 years ago now, we first mentioned a surgical technique known as “Retzius-sparing” radical prostatectomy on this web site. … READ MORE …

The ADVANCED prostate cancer needs survey

A researcher at the Medical University of South Carolina (MUSC) College of Nursing is conducting a study to better understand supportive care needs and quality of life among individuals with ADVANCED forms of prostate cancer and is seeking just a few more participants to complete this survey. Can you help (if you haven’t already)? … READ MORE …